The Zhitong Finance App learned that Cinda Biotech (01801) rose more than 3%. As of press release, it had risen 3.28% to HK$93, with a turnover of HK$101 million.

According to news, on July 14, according to Cinda Biotech's official WeChat account, the company and Spero Therapeutics, Inc. (NASDAQ: SPRO, “Spero”) announced that the two parties had reached an exclusive licensing agreement for IBI355 (Spero R&D code: SP001) - the third-generation FC silent anti-CD40L antibody.

Under the agreement, Cinda Biotech granted Spero the exclusive right to develop, research, produce and commercialize IBI355 on a global scale outside of Greater China; Cinda Biotech reserves the rights to the product in Greater China. SPERO plans to launch a Phase II clinical study of IBI355 for IgG4-RD patients in the second quarter of 2027; Cinda Biotech plans to launch a phase II clinical study of IBI355 treatment of SJD in China by early 2027.

Under the terms of the agreement, Cinda Biotech will receive a down payment and milestone payments related to development, registration and sales, totaling approximately US$1.1 billion. At the same time, Cinda Biotech will also receive a gradient sales share based on the product's net sales in the future.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.